{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T20:56:20Z","timestamp":1771102580212,"version":"3.50.1"},"reference-count":222,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s40264-023-01285-5","type":"journal-article","created":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T07:02:07Z","timestamp":1684825327000},"page":"517-532","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Communicating for the Safe Use of Medicines: Progress and Directions for the 2020s Promoted by the Special Interest Group of the International Society of Pharmacovigilance"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7798-6117","authenticated-orcid":false,"given":"Priya","family":"Bahri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoffrey","family":"Bowring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian D.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Anton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey K.","family":"Aronson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Caro-Rojas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce P. J.","family":"Hugman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter G.","family":"Mol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluca","family":"Trifir\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarina","family":"Ilic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riadh","family":"Daghfous","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Fermont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Furlan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Gaissmaier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Ishaq","family":"Geer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth Y.","family":"Hartigan-Go","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Hou\u00ffez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hansj\u00f6rg","family":"Neth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gediminas","family":"Norgela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaowares","family":"Oppamayun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. K. Theo","family":"Raynor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehdi","family":"Bouhlel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet","family":"Sultana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,23]]},"reference":[{"key":"1285_CR1","unstructured":"Special Interest Group on Medicinal Product Risk Communication of the International Society of Pharmacovigilance (ISoP CommSIG). https:\/\/isoponline.org\/special-interest-groups\/risk-communication-group\/. Accessed 19 Sept 2020."},{"key":"1285_CR2","unstructured":"Erice Declaration: effective communications in pharmacovigilance (report of the International Conference on Developing Effective Communications in Pharmacovigilance held in Erice, 24-27 September 1997, organised by the Uppsala Monitoring Centre (UMC), the Clinical Pharmacology Unit of Verona University, the International School of Pharmacology of the Ettore Majorana Centre for Scientific Culture in Erice, Italy and the World Health Organization, and supported by EQUUS Communications, London). Uppsala: UMC; 1997."},{"issue":"69","key":"1285_CR3","first-page":"207","volume":"2010","author":"E Statement","year":"2009","unstructured":"Statement E. communication, medicines and patient safety (report of the Workshop on Drug Risk Communication held in Erice, 3\u20138 July 2009, organised by the International School of Pharmacology at the Ettore Majorana Foundation and Centre for Scientific Culture in Erice, Italy, in collaboration with the International Society of Pharmacovigilance (ISoP), the SK Foundation and the Uppsala Monitoring Centre (UMC)). Br J Clin Pharmacol. 2009;2010(69):207\u20138.","journal-title":"Br J Clin Pharmacol"},{"key":"1285_CR4","doi-asserted-by":"crossref","unstructured":"Bahri P, Dodoo AN, Edwards BD, Edwards IR, Fermont I, Hagemann U, Hartigan-Go K, Hugman B, Mol PG; on behalf of the ISoP CommSIG. The ISoP CommSIG for Improving Medicinal Product Risk Communication: A New Special Interest Group of the International Society of Pharmacovigilance. Drug Saf. 2015; 38:621\u201327.","DOI":"10.1007\/s40264-015-0301-0"},{"key":"1285_CR5","unstructured":"14th Annual Meeting of ISoP. https:\/\/isoponline.org\/annual-meetings\/isop-2014-annual-meeting\/. Accessed 30 Jan 2022."},{"key":"1285_CR6","unstructured":"International Society of Pharmacovigilance (ISoP). Special interest groups: women\u2019s medicines. https:\/\/isoponline.org\/special-interest-groups\/womens-medicines-group\/. Accessed 12 Feb 2022."},{"key":"1285_CR7","unstructured":"International Society of Pharmacovigilance (ISoP). Special interest groups: herbal and traditional medicines. https:\/\/isoponline.org\/special-interest-groups\/herbal-and-traditional-medicines-2\/. Accessed 12 Feb 2022."},{"key":"1285_CR8","unstructured":"International Society of Pharmacovigilance (ISoP). Special interest groups: medication errors. https:\/\/isoponline.org\/special-interest-groups\/medication-errors\/. Accessed 13 May 2021."},{"key":"1285_CR9","unstructured":"International Society of Pharmacovigilance (ISoP). Special interest groups: vaccines. https:\/\/isoponline.org\/special-interest-groups\/vaccine-surveillance\/. Accessed 13 May 2021."},{"key":"1285_CR10","unstructured":"International Society of Pharmacovigilance (ISoP). Special interest groups: risk minimisation methods for Asian countries. https:\/\/isoponline.org\/special-interest-groups\/risk-minimisation-methods-for-asian-countries\/. Accessed 12 Feb 2022."},{"key":"1285_CR11","unstructured":"International Society of Pharmacovigilance (ISoP). Special interest groups: patient engagement. https:\/\/isoponline.org\/special-interest-groups\/isop-patient-engagement-group\/#. Accessed 12 Feb 2022."},{"key":"1285_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40264-017-0603-5","volume":"41","author":"D McCarthy","year":"2018","unstructured":"McCarthy D, Bahri P, Barnes J, Delumeau J-C, Edwards B, Harrison-Woolrych M. An update on ISoP special interest groups (SIGs). Drug Saf. 2018;41:1\u20136.","journal-title":"Drug Saf"},{"key":"1285_CR13","unstructured":"Bahri P. Transparency, communication and participation in pharmacovigilance [presentation]. In: Accra: 2nd African Society of pharmacovigilance conference; 25\u201327 November 2015."},{"key":"1285_CR14","unstructured":"Bahri P, Schaefer C (moderator: Hageman U). From risk perception to risk communication [training session]. Berlin: Training Course on Risk Assessment of Drug Use During Pregnancy and Lactation\u201d, organised by the European Network of Teratology Information Services (ENTIS) and the International Society of Pharmacovigilance (ISoP) in collaboration with the Norwegian PhD School in Pharmacy (NFIF); 2\u20133 June 2016."},{"key":"1285_CR15","unstructured":"Fermont RI, Amitai A, Livneh A, Kalamaro V, Litman R, Pitts P, Sevdalis N, Bahri P, Edwards B, Elad A. National campaign in an Israeli chain of community-based pharmacies to decrease the risks of anticoagulants [conference abstract]. Drug Saf. 2018;41:1111 (abstract O-014)."},{"key":"1285_CR16","unstructured":"Israeli Chapter of ISoP. 360\u00b0 of drug safety: minimize risks, improve communication\u20141st ISoP Israel international symposium, Tel Aviv, 3\u20134 June 2019. https:\/\/www.isopisrael2019.org. Accessed 13 May 2021."},{"key":"1285_CR17","unstructured":"International Society of Pharmacovigilance (ISoP). Resources: infographics. https:\/\/isoponline.org\/resources-3\/infographics\/. Accessed 13 May 2021."},{"key":"1285_CR18","unstructured":"Caro-Rojas A. The ISoP infographics and the ISoP communication strategy: new ways for outreach of our Society [presentation]. In: 20th annual meeting of the international society of pharmacovigilance (ISoP) in Muscat, 9 November 2021."},{"key":"1285_CR19","unstructured":"Israeli Chapter of ISoP. 2nd online summit: drug safety in the COVID area. 2020. https:\/\/www.isopisrael.org.il\/drug-safety-in-the-covid-era. Accessed 13 May 2021."},{"key":"1285_CR20","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s40264-020-00965-w","volume":"43","author":"M Tuccori","year":"2020","unstructured":"Tuccori M, Convertino I, Ferraro S, Cappello E, Valdiserra G, Focosi D, Blandizzi C. The impact of the COVID-19 \u201cInfodemic\u201d on drug-utilization behaviors: implications for pharmacovigilance. Drug Saf. 2020;43:699\u2013709.","journal-title":"Drug Saf"},{"key":"1285_CR21","unstructured":"Israeli Chapter of ISoP. Tell us a safety story\u2014season 2 [webinar series]. 4 November\u201323 December 2020. https:\/\/isoponline.org\/wp-content\/uploads\/2020\/10\/20201104-AGENDA-Safety-Case-Story.pdf. Accessed 13 May 2021."},{"key":"1285_CR22","doi-asserted-by":"crossref","unstructured":"Bahri P, Morales DR, A Inoubli, Dogn\u00e9 JM, Straus SMJM. Proposals for engaging patients and healthcare professionals in risk minimisation from an analysis of stakeholder input to the EU valproate assessment using the novel Analysing Stakeholder Safety Engagement Tool (ASSET). Drug Saf. 2021;44:193\u2013209 (epub 30 Oct 2020).","DOI":"10.1007\/s40264-020-01005-3"},{"key":"1285_CR23","unstructured":"Latin American Chapter of ISoP. Vigilance of COVID-19 vaccines [webinar series]. 2021. https:\/\/isoponline.org\/wp-content\/uploads\/2021\/02\/web-announcement-29012021-scaled.jpg. Accessed 13 May 2021."},{"key":"1285_CR24","unstructured":"Bahri P. Communication of safety signals: what, when and where [training]. 20th Annual Meeting of the International Society of Pharmacovigilance (ISoP). Pre-conference course programme. Muscat. 2021. https:\/\/www.isop2021oman.org\/wp-content\/uploads\/2021\/09\/2021110204-ISoP-2021-pre-conference-training-course-II-preliminary-programme-20210908_EvP2.pdf. Accessed 12 Feb 2022."},{"key":"1285_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-981-15-3013-5","volume-title":"Communicating about risks and safe use of medicines: real life and applied research","author":"P Bahri","year":"2020","unstructured":"Bahri P. A multilayered research framework for humanities and epidemiology of medicinal product risk communication. In: Bahri P, editor. Communicating about risks and safe use of medicines: real life and applied research. Singapore: Springer; 2020. p. 1\u201384."},{"key":"1285_CR26","first-page":"960","volume":"38","author":"H Neth","year":"2015","unstructured":"Neth H. Risk Factors, psychology and communication [conference abstract]. Drug Saf. 2015;38:960 (abstract\u00a0O57).","journal-title":"Drug Saf"},{"key":"1285_CR27","first-page":"960","volume":"38","author":"DK Raynor","year":"2015","unstructured":"Raynor DK. Talking about harm and benefit information: the challenges in healthcare practice [conference abstract]. Drug Saf. 2015;38:960 (abstract\u00a0O56).","journal-title":"Drug Saf"},{"key":"1285_CR28","unstructured":"Hou\u00ffez F. Communicating on risks: clear questions, clear responses? [presentation]. In: Geneva: 18th annual meeting of the international society of pharmacovigilance; 11\u201314 November 2018."},{"key":"1285_CR29","unstructured":"Wessling S. Coordinated communication in crises and in everyday work [presentation]. In: Geneva: 18th annual meeting of the international society of pharmacovigilance; 11\u201314 November 2018."},{"key":"1285_CR30","unstructured":"Nazakat S. Visualised information: experiences from Asia with digital media [presentation]. In: 20th annual meeting of the international society of pharmacovigilance (ISoP) in Muscat, 9 November 2021."},{"key":"1285_CR31","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/BF03261984","volume":"35","author":"P Bahri","year":"2012","unstructured":"Bahri P, Harrison-Woolrych M. Focussing on risk communication about medicines: why now? [editorial]. Drug Saf. 2012;35:971\u20135. https:\/\/doi.org\/10.1007\/BF03261984.","journal-title":"Drug Saf"},{"key":"1285_CR32","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1007\/BF03261985","volume":"35","author":"AR Cox","year":"2012","unstructured":"Cox AR, Butt TF. Adverse drug reactions: when the risk becomes a reality for patients. Drug Saf. 2012;35:977\u201381.","journal-title":"Drug Saf"},{"key":"1285_CR33","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/BF03261986","volume":"35","author":"B Fischhoff","year":"2012","unstructured":"Fischhoff B. Good decision making requires good communication. Drug Saf. 2012;35:983\u201393.","journal-title":"Drug Saf"},{"key":"1285_CR34","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/BF03261987","volume":"35","author":"K Hartigan-Go","year":"2012","unstructured":"Hartigan-Go K. Challenges of drug risk communication in the Philippines. Drug Saf. 2012;35:995\u20131004.","journal-title":"Drug Saf"},{"key":"1285_CR35","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1007\/BF03261988","volume":"35","author":"B Hugman","year":"2012","unstructured":"Hugman B. Protecting the people?: risk communication and the chequered history and performance of bureaucracy. Drug Saf. 2012;35:1005\u201325.","journal-title":"Drug Saf"},{"key":"1285_CR36","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/BF03261989","volume":"35","author":"B Edwards","year":"2012","unstructured":"Edwards B, Chakraborty S. Risk communication and the pharmaceutical industry: what is the reality. Drug Saf. 2012;35:1027\u201340.","journal-title":"Drug Saf"},{"key":"1285_CR37","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/BF03261990","volume":"35","author":"A Dodoo","year":"2012","unstructured":"Dodoo A, Hugman B. Risk perception and communication in Sub-Saharan Africa. Drug Saf. 2012;35:1041\u201352.","journal-title":"Drug Saf"},{"key":"1285_CR38","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/BF03261991","volume":"35","author":"H Larson","year":"2012","unstructured":"Larson H, Brocard Paterson P, Erondu N. The globalisation of risk and risk perception: why we need a new model of risk communication for vaccines. Drug Saf. 2012;35:1053\u20139.","journal-title":"Drug Saf"},{"key":"1285_CR39","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1007\/BF03261992","volume":"35","author":"S Piening","year":"2012","unstructured":"Piening S, Haaijer-Ruskamp FM, de Graeff PA, Straus SMJM, Mol PGM. Healthcare professionals\u2019 self-reported experiences and preferences related to direct healthcare professional communications: a survey conducted in the Netherlands. Drug Saf. 2012;35:1061\u201372.","journal-title":"Drug Saf"},{"key":"1285_CR40","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.2165\/11539040-000000000-00000","volume":"33","author":"P Bahri","year":"2010","unstructured":"Bahri P. Public pharmacovigilance communication: a process calling for evidence-based, objective-driven strategies. Drug Saf. 2010;33:1065\u201379.","journal-title":"Drug Saf"},{"key":"1285_CR41","unstructured":"Fischhoff B, Brewer NT, Downs JS, editors. Communicating risks and benefits: an evidence-based user\u2019s guide. Silver Spring, MA: US Food and Drug Administration; 2011. https:\/\/www.fda.gov\/about-fda\/reports\/communicating-risks-and-benefits-evidence-based-users-guide. Accessed 13 May 2021."},{"key":"1285_CR42","unstructured":"Winstanley G. Safety issue communication requirements [presentation]. In: Bogot\u00e1: 19th annual meeting of the international society of pharmacovigilance; 26\u201329 October 2019."},{"key":"1285_CR43","first-page":"1029","volume":"39","author":"JC Delumeau","year":"2016","unstructured":"Delumeau JC, Le Louet H, Moride Y, Chen WW, Suwankesawong W, Nguyen HA. A model to guide designing risk-proportionate risk minimisation and vigilance programs [conference abstract]. Drug Saf. 2016;39:1029 (abstract\u00a0P083).","journal-title":"Drug Saf"},{"key":"1285_CR44","first-page":"1111","volume":"41","author":"A Caro-Rojas","year":"2018","unstructured":"Caro-Rojas A. Health care communication empowerment: a successful programme in Colombia [conference abstract]. Drug Saf. 2018;41:1111 (abstract\u00a0O-012).","journal-title":"Drug Saf"},{"key":"1285_CR45","first-page":"1010","volume":"39","author":"MI Geer","year":"2016","unstructured":"Geer MI, Shah PA, Masoodi SR, Dar PA, Jan M, Iqbal MJ, Khan AM, Zahida A, Mir J, Kumar TA. Drug utilization evaluation as a tool for minimizing risk and promoting rational use of medicines [conference abstract]. Drug Saf. 2016;39:1010 (abstract\u00a0P040).","journal-title":"Drug Saf"},{"key":"1285_CR46","unstructured":"Palacios JM. Theatre in indigenous populations and pharmacovigilance [presentation]. In: Bogot\u00e1: 19th annual meeting of the international society of pharmacovigilance; 26\u201329 October 2019."},{"key":"1285_CR47","first-page":"1022","volume":"39","author":"Y Oppamayun","year":"2016","unstructured":"Oppamayun Y, Suwankaesawong W, Rattanaphan C. Communication tool for better safety outcome in using medicines [conference abstract]. Drug Saf. 2016;39:1022 (abstract\u00a0P066).","journal-title":"Drug Saf"},{"key":"1285_CR48","unstructured":"Macolic\u0301 \u0160arinic\u0301 V. Risk communication in the European Union: highlights from Croatia as a regional example [conference abstract]. Drug Saf. 2015;38:959 (abstract O55)"},{"key":"1285_CR49","unstructured":"Sultana J, Giorgianni F, Tillati S, Sturkenboom M, G Trifiro. Did the safety warnings minimize the risk of antipsychotic-related stroke in elderly people with dementia? [conference abstract]. Drug Saf. 2016;39:1019 (abstract P061)."},{"key":"1285_CR50","first-page":"1111","volume":"41","author":"M Bouhlel","year":"2018","unstructured":"Bouhlel M, Daghfous R, El Aidli S. Central to risk communication in healthcare: the national pharmacovigilance centre in Tunisia [conference abstract]. Drug Saf. 2018;41:1111 (abstract\u00a0O-013).","journal-title":"Drug Saf"},{"key":"1285_CR51","unstructured":"Hugman BPJ. Urgent and important: good information on medicines for women worldwide [presentation]. In: Geneva: 18th annual meeting of the International Society of Pharmacovigilance; 11\u201314 November 2018."},{"key":"1285_CR52","unstructured":"The Health Communication Capacity Collaborative. The P-Process: five steps to strategic communication. Baltimore, MD: Johns Hopkins Bloomberg School of Public Health Center for Communication Programs; 2013 (developed in 1982). http:\/\/www.thehealthcompass.org\/sbcc-tools\/p-process. Accessed 13 May 2021."},{"key":"1285_CR53","first-page":"1110","volume":"41","author":"B Edwards","year":"2018","unstructured":"Edwards B. Human factor science for improving the impact of risk communication [conference abstract]. Drug Saf. 2018;41:1110 (abstract\u00a0O-011).","journal-title":"Drug Saf"},{"key":"1285_CR54","unstructured":"Charted Institute of Ergonomics & Human Factors (CIEHF). What is ergonomics: find out how it makes life better. Birmingham: CIEHF. https:\/\/www.ergonomics.org.uk\/Public\/Resources\/What_is_Ergonomics_\/Public\/Resources\/What_is_Ergonomics_.aspx?hkey=2769db3e-4b5b-46c2-864c-dfcf2e44372d. Accessed 2 Sept 2019."},{"key":"1285_CR55","unstructured":"National Center for Human Factors in Healthcare. What is human factors in healthcare? Washington, DC: National Center for Human Factors in Healthcare. Human factors in healthcare. Accessed 8 Jun 2019."},{"key":"1285_CR56","doi-asserted-by":"crossref","unstructured":"Tsukahara VHB, Calil SJ. Root cause analysis combined with human factors engineering tools for adverse events investigation in healthcare. In: Kyriacou E, Christofides S, Pattichis C, editors. XIV Mediterranean conference on medical and biological engineering and computing 2016 [IFMBE Proceedings, Vol 57]. Springer, 2016.","DOI":"10.1007\/978-3-319-32703-7_201"},{"key":"1285_CR57","first-page":"1215","volume":"42","author":"F Santoro","year":"2019","unstructured":"Santoro F, Norg\u00e8la G. #MedSafetyWeek: joining forces on social media to raise ADR awareness [conference abstract]. Drug Saf. 2019;42:1215 (abstract\u00a019).","journal-title":"Drug Saf"},{"key":"1285_CR58","unstructured":"Bahri P, Edwards BD. Patient safety through dialogue: how to better connect pharmacovigilance and healthcare? [conference abstract]. Drug Saf. 2015; 38: 959 (abstract O53). (Bengt Erik Wiholm Lecture. In: Prague: 15th annual meeting of the International Society of Pharmacovigilance (ISoP); 27\u201330 October 2015)."},{"key":"1285_CR59","first-page":"1110","volume":"41","author":"P Bahri","year":"2018","unstructured":"Bahri P, Ilic K, Hagemann U. Communication: the key to implementation of risk management and patient safety [conference abstract]. Drug Saf. 2018;41:1110 (abstract\u00a0O-010).","journal-title":"Drug Saf"},{"key":"1285_CR60","unstructured":"Bahri P, Dodoo AN. Risk communication\u2014\u201cSnakes and Ladders\u201d and a strategic approach to risk minimisation in healthcare [slides for introduction by session chairs]. In: Agra: 16th annual meeting of the International Society of Pharmacovigilance (ISoP); 16\u201319 October 2016."},{"key":"1285_CR61","unstructured":"Mol PGM; on behalf of SCOPE work package 6. Healthcare professionals\u2019 perspectives on regulatory safety communication about medicines: the Strengthening Collaboration for Operating Pharmacovigilance in Europe (SCOPE) joint action [conference abstract]. Drug Saf. 2015;38:959 (abstract O54)."},{"key":"1285_CR62","first-page":"1249","volume":"42","author":"C Anton","year":"2019","unstructured":"Anton C, Coleman J, Ferner R, New T, Pontefract S. Systematic instructions for haematological monitoring in summary of product characteristics: what constitutes good practice [conference abstract]. Drug Saf. 2019;42:1249 (abstract\u00a087).","journal-title":"Drug Saf"},{"key":"1285_CR63","unstructured":"Sless D, Wiseman R. Writing about medicines for people: Usability guidelines for consumer medicine information. 2nd ed. Canberra: Department of Health and Family Services; 1997."},{"key":"1285_CR64","unstructured":"European Commission (EC). Guideline on the readability of the labelling and package leaflet of medicinal products for human use. Rev 1. Brussels: EC; 2009. https:\/\/ec.europa.eu\/health\/sites\/default\/files\/files\/eudralex\/vol-2\/c\/2009_01_12_readability_guideline_final_en.pdf. Accessed 13 May 2021."},{"key":"1285_CR65","unstructured":"Medicines and Healthcare products Regulatory Agency (MHRA). Always read the leaflet [report of the Committee on Safety of Medicines, Working Group on Patient Information]. London: MHRA; 2005."},{"key":"1285_CR66","unstructured":"Minister of Health, Canada. Strategic risk communications framework and handbook. Ottawa: Minister of Health, Canada; 2006."},{"key":"1285_CR67","unstructured":"European Commission (EC). Volume 9A of the Rules Governing Medicinal Products in the EU: pharmacovigilance guidelines. Brussels: EC; 2006: Chapter IV.2."},{"key":"1285_CR68","volume-title":"Guide for using the standardized health product risk communication template","author":"H Canada","year":"2015","unstructured":"Canada H. Guide for using the standardized health product risk communication template. Ottawa: Health Canada; 2015."},{"key":"1285_CR69","doi-asserted-by":"crossref","unstructured":"Bhasale AL, Sarpatwari A, De Bruin ML, Lexchin J, Lopert R, Bahri P, Mintzes BJ. Post-market safety communication for protection of public health: a comparison of regulatory policy in Australia, Canada, the European Union, and the United States. Clin Pharmacol Ther. 2020 (epub).","DOI":"10.1002\/cpt.2010"},{"issue":"5","key":"1285_CR70","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1248\/yakushi.132.561","volume":"132","author":"M Hirose","year":"2012","unstructured":"Hirose M. Risk communication with patients (abstract in English)] [Japanese]. Yakugaku Zasshi. 2012;132(5):561\u20132. https:\/\/doi.org\/10.1248\/yakushi.132.561.","journal-title":"Yakugaku Zasshi"},{"issue":"2","key":"1285_CR71","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1248\/yakushi.14-00232-1","volume":"135","author":"M Isozaki","year":"2015","unstructured":"Isozaki M. Present state and future tasks of \u201cDrug Guide for Patients\u201d (abstract in English)] [Japanese]. Yakugaku Zasshi. 2015;135(2):271\u2013175. https:\/\/doi.org\/10.1248\/yakushi.14-00232-1.","journal-title":"Yakugaku Zasshi"},{"issue":"3","key":"1285_CR72","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1248\/yakushi.17-00185-2","volume":"138","author":"E Kondo","year":"2018","unstructured":"Kondo E, Torii M, Oba I, Okamoto M. The Pharmaceuticals and Medical Devices Agency\u2019s approach to facilitate risk communication and its challenges (abstract in English)] [Japanese]. Yakugaku Zasshi. 2018;138(3):307\u201314. https:\/\/doi.org\/10.1248\/yakushi.17-00185-2.","journal-title":"Yakugaku Zasshi"},{"key":"1285_CR73","unstructured":"European Medicines Agency (EMA). Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium (PROTECT): results and their impact on regulatory practice [report]. London: EMA; 2016. http:\/\/www.imi-protect.eu\/documents\/ReportImpactPROTECT_002.pdf. Accessed 13 May 2021."},{"key":"1285_CR74","unstructured":"Hughes D, Waddingham EAJ, Mt-Isa S, Goginsky A, Chan E, Downey G, Hallgreen CE, Hockley KS, Juhaeri J, Lieftucht A, Metcalfe MA, Noel RA, Phillips L, Ashby D, Micaleff A; on behalf of the Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium (PROTECT) Work Package 5. Recommendations for the methodology and visualisation techniques to be used in the assessment of benefit and risk of medicines [undated]. http:\/\/www.imi-protect.eu\/documents\/HughesetalRecommendationsforthemethodologyandvisualisationtechniquestobeusedintheassessmento.pdf. Accessed 13 May 2021."},{"key":"1285_CR75","unstructured":"Larson H, Karafillakis E, Yiangou A, Bahri P, Fogd J, Kurz J, et al.; ADVANCE consortium. Developing communication strategies on vaccine benefits and risks: guidance for public-private collaborations. Accelerated Development of VAccine beNefit-risk Collaboration in Europe (ADVANCE); 2017. https:\/\/vac4eu.org\/results-communication\/. Accessed 13 May 2021."},{"key":"1285_CR76","doi-asserted-by":"crossref","unstructured":"Karafillakis E, Larson HJ; ADVANCE consortium. The benefit of the doubt or doubts over benefits? A systematic literature review of perceived risks of vaccines in European populations. Vaccines. 2017;35:4840\u201350.","DOI":"10.1016\/j.vaccine.2017.07.061"},{"key":"1285_CR77","doi-asserted-by":"crossref","unstructured":"Bahri P, Fogd J, Morales D, Kurz X, ADVANCE consortium. Application of real-time global media monitoring and \u2018derived questions\u2019 for enhancing communication by regulatory bodies: the case of human papillomavirus vaccines. BMC Med. 2017;15:91.","DOI":"10.1186\/s12916-017-0850-4"},{"key":"1285_CR78","unstructured":"Montero D. SCOPE joint action work package 6 on risk communication [presentation]. 2016. https:\/\/www.ema.europa.eu\/en\/documents\/presentation\/presentation-scope-joint-action-work-package-6-risk-communication-dolores-montero_en.pdf. Accessed 13 May 2021."},{"key":"1285_CR79","doi-asserted-by":"crossref","unstructured":"Radecka A, Loughlin L, Foy M, de Ferraz Guimaraes MV, Macolic Sarinic V, Dimov Di Giusti, Lesicar M, Straus S, Montero D, Pallos J, Ivanovic J, Raine J. Enhancing pharmacovigilance capabilities in the EU regulatory network: the SCOPE Joint Action. Drug Saf. 2018;41:1285\u2013302.","DOI":"10.1007\/s40264-018-0708-5"},{"key":"1285_CR80","unstructured":"The National Academies of Sciences, Engineering and Medicines. In: Communicating clearly about medicines: Proceedings of a workshop. Washington, DC: The National Academies Press; 2017."},{"key":"1285_CR81","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s40264-015-0291-y","volume":"38","author":"AS Kesselheim","year":"2015","unstructured":"Kesselheim AS, Campbell EG, Schneeweiss S, Rausch P, Lappin BM, Zhou EH, Seeger JD, Brownstein JS, Woloshin S, Schwartz LM, Toomey T, Dal Pan GJ, Avorn J. Methodological approaches to evaluate the impact of FDA drug safety communications. Drug Saf. 2015;38:565\u201375.","journal-title":"Drug Saf"},{"key":"1285_CR82","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s40264-017-0516-3","volume":"40","author":"AS Kesselheim","year":"2017","unstructured":"Kesselheim AS, McGraw AS, Dejene SZ, Rausch P, Dal Pan GJ, Lappin BM, Zhou EH, Avorn J, Campbell EG. Patient and physician perceptions of drug safety information for sleep aids: a qualitative study. Drug Saf. 2017;40:531\u201342.","journal-title":"Drug Saf"},{"key":"1285_CR83","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s40264-019-00849-8","volume":"42","author":"AS Kesselheim","year":"2019","unstructured":"Kesselheim AS, Sinha MS, Campbell EG, Schneeweiss S, Rausch P, Lappin BM, Zhou EH, Avorn J, Dal Pan GJ. Multimodal analysis of FDA drug safety communications: lessons from zolpidem. Drug Saf. 2019;42:1287\u201395.","journal-title":"Drug Saf"},{"key":"1285_CR84","doi-asserted-by":"publisher","DOI":"10.2196\/publichealth.7823","volume":"4","author":"MS Sinha","year":"2018","unstructured":"Sinha MS, Freifeld CC, Brownstein JS, Donneyong MM, Rausch P, Lappin BM, Zhou EH, Dal Pan GJ, Pawar AM, Hwang TJ, Avorn J, Kesselheim AS. Social media impact of the Food and Drug Administration\u2019s drug safety communication messaging about zolpidem: mixed-methods analysis. JMIR Public Health Surveill. 2018;4: e1.","journal-title":"JMIR Public Health Surveill"},{"key":"1285_CR85","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1080\/10810730.2016.1266717","volume":"22","author":"S Woloshin","year":"2017","unstructured":"Woloshin S, Schwartz LM, Dejene S, Rausch P, Dal Pan GJ, Zhou EH, Kesselheim AS. Media coverage of FDA drug safety communications about zolpidem: a quantitative and qualitative analysis. J Health Commun. 2017;22:365\u201372.","journal-title":"J Health Commun"},{"key":"1285_CR86","unstructured":"Independent Medicines and Medical Devices Safety Review, United Kingdom. First do no harm [report]. London: Government of the United Kingdom of Great Britain and Northern Ireland; 2020."},{"key":"1285_CR87","unstructured":"European Medicines Agency (EMA) and Heads of Medicines Agencies (HMA). Guideline on good pharmacovigilance practices\u2014module XVI on risk minimisation measures: selection of tools and\u00a0effectiveness indicators (rev 3) and Addendum II on Methods for effectiveness evaluation. Amsterdam: EMA; 2021. https:\/\/www.ema.europa.eu\/en\/human-regulatory\/post-authorisation\/pharmacovigilance\/good-pharmacovigilance-practices#public-consultations-section. Accessed 13 May 2021."},{"key":"1285_CR88","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s40264-017-0571-9","volume":"40","author":"IR Edwards","year":"2017","unstructured":"Edwards IR. A new Erice Report considering the safety of medicines in the 21st century. Drug Saf. 2017;40:845\u20139.","journal-title":"Drug Saf"},{"key":"1285_CR89","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s40264-020-00919-2","volume":"43","author":"E Rocca","year":"2020","unstructured":"Rocca E, Anjum RL. Erice call for change: utilising patient experiences to enhance the quality and safety of healthcare. Drug Saf. 2020;43:513\u20135.","journal-title":"Drug Saf"},{"key":"1285_CR90","unstructured":"Council for International Organizations of Medical Sciences (CIOMS). https:\/\/cioms.ch. Accessed 13 May 2021."},{"key":"1285_CR91","unstructured":"Council for International Organizations of Medical Sciences (CIOMS). CIOMS guide on vaccine safety communication. Geneva: CIOMS; 2017. https:\/\/cioms.ch\/publications\/product\/cioms-guide-vaccine-safety-communication. Accessed 13 May 2021."},{"key":"1285_CR92","doi-asserted-by":"crossref","unstructured":"Bahri P, R\u00e4go L; on behalf of the CIOMS Working Group on Vaccine Safety. CIOMS guide to vaccine safety communication: executive summary. Vaccine. 2019;37:401\u20138.","DOI":"10.1016\/j.vaccine.2018.11.082"},{"key":"1285_CR93","unstructured":"Council for International Organizations of Medical Sciences (CIOMS). Working Group XI: patient involvement in development and safe use of medicines. https:\/\/cioms.ch\/working-groups\/working-group-xi-patient-involvement. Accessed 13 May 2021."},{"key":"1285_CR94","unstructured":"World Health Organization (WHO). The WHO Programme for International Drug Monitoring. Geneva: WHO. https:\/\/www.who.int\/medicines\/regulation\/medicines-safety\/about\/drug_monitoring_prog\/en\/. Accessed 13 May 2021."},{"key":"1285_CR95","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1007\/BF03261993","volume":"35","author":"P Bahri","year":"2012","unstructured":"Bahri P, Harrison-Woolrych M. How to improve communication for the safe use of medicines?: discussions on social marketing and patient-tailored approaches at the annual meetings of the WHO Programme for International Drug Monitoring. Drug Saf. 2012;35:1073\u20139.","journal-title":"Drug Saf"},{"key":"1285_CR96","unstructured":"World Health Organization (WHO). Pharmacovigilance resources. Geneva: WHO. https:\/\/whopvresources.org. Accessed 13 Mar 2022."},{"key":"1285_CR97","unstructured":"Uppsala Monitoring Centre (UMC). Uppsala: UMC. https:\/\/www.who-umc.org. Accessed 13 May 2021."},{"key":"1285_CR98","unstructured":"International Society for Pharmacoepidemiology. Special Interest Group in Benefit-Risk Assessment, Communication and Evaluation (BRACE). https:\/\/www.pharmacoepi.org\/communities\/sigs\/brace. Accessed 13 May 2021."},{"key":"1285_CR99","doi-asserted-by":"crossref","unstructured":"Radawski C, Morrato E, Hornbuckle K, Bahri P, Smith M, Juhaeri J, Mol P, Levitan B, Huang H-Y, Coplan P, Li H; on behalf of the ISPE BRACE SIG. Benefit-risk assessment, communication and evaluation (BRACE) throughout the life cycle of therapeutic products: overall perspective and role of the pharmacoepidemiologist. Pharmacoepidemiol Drug Saf. 2015;24:1233\u201340.","DOI":"10.1002\/pds.3859"},{"key":"1285_CR100","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1002\/pds.5167","volume":"29","author":"CA Radawski","year":"2020","unstructured":"Radawski CA, Hammad TA, Colilla S, Coplan P, Hornbuckle K, Freeman E, Smith MY, Sobel RE, Bahri P, Arias AE, Bennett D. The utility of real-world evidence for benefit-risk assessment, communication, and evaluation of pharmaceuticals: case studies. Pharmacoepidemiol Drug Saf. 2020;29:1532\u20139.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1285_CR101","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s40264-017-0619-x","volume":"41","author":"MY Smith","year":"2018","unstructured":"Smith MY, Russel A, Bahri P, Mol PGM, Frise S, Freeman E, Morrato EH. The RIMES Statement: a checklist to assess the quality of studies evaluating risk minimization programs for medicinal products. Drug Saf. 2018;41:389\u2013401.","journal-title":"Drug Saf"},{"key":"1285_CR102","unstructured":"Bahri P, ElShafie S, Ho\u00ffez F, Leufkens HG, Morrato EH, Wegwarth O. Science communication of pharmacoepidemiology for patient and public health [plenary session]. In: ICPE All Access online conference; 2020."},{"key":"1285_CR103","unstructured":"Smith MY, Bahri P, Hou\u00ffez F, Lo Re V. Communicating COVID-19 pharmacoepidemiological research to patients [plenary session]. In: ICPE All Access online conference; 2021."},{"key":"1285_CR104","volume-title":"Medicines for women","year":"2015","unstructured":"Harrison-Woolrych M, editor. Medicines for women. Cham: Springer; 2015."},{"key":"1285_CR105","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/978-3-319-12406-3_18","volume-title":"Medicines for women","author":"B Hugman","year":"2015","unstructured":"Hugman B. Perspectives on risk communication and gender issues. In: Harrison-Woolrych M, editor. Medicines for women. Cham: Springer; 2015. p. 531\u201383."},{"key":"1285_CR106","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/978-3-319-12406-3_19","volume-title":"Medicines for women","author":"B Hugman","year":"2015","unstructured":"Hugman B. Risk communication and specific medicines for women. In: Harrison-Woolrych M, editor. Medicines for women. Cham: Springer; 2015. p. 585\u2013627."},{"key":"1285_CR107","volume-title":"Pharmacovigilance: critique and ways forward","year":"2017","unstructured":"Edwards IR, Lindquist M, editors. Pharmacovigilance: critique and ways forward. Cham: Springer; 2017."},{"key":"1285_CR108","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/978-3-319-40400-4_9","volume-title":"Pharmacovigilance: critique and ways forward","author":"B Hugman","year":"2017","unstructured":"Hugman B. Shaking up culture and communication in PV. In: Edwards IR, Lindquist M, editors. Pharmacovigilance: critique and ways forward. Cham: Springer; 2017. p. 81\u201397."},{"key":"1285_CR109","doi-asserted-by":"crossref","unstructured":"Bahri P, editor. Communicating about risks and safe use of medicines: real life and applied research. Singapore: Springer; 2020.","DOI":"10.1007\/978-981-15-3013-5"},{"key":"1285_CR110","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/978-981-15-3013-5_11","volume-title":"Communicating about risks and safe use of medicines: real life and applied research","author":"N Dasgupta","year":"2020","unstructured":"Dasgupta N, Winokur C, Pierce C. Social media research. In: Bahri P, editor. Communicating about risks and safe use of medicines: real life and applied research. Singapore: Springer; 2020. p. 307\u201332."},{"key":"1285_CR111","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/978-981-15-3013-5_12","volume-title":"Communicating about risks and safe use of medicines: real life and applied research","author":"J Fuchs","year":"2020","unstructured":"Fuchs J. Design science with a focus on user-centred evaluation of written information. In: Bahri P, editor. Communicating about risks and safe use of medicines: real life and applied research. Singapore: Springer; 2020. p. 333\u201384."},{"key":"1285_CR112","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/978-981-15-3013-5_16","volume-title":"Communicating about risks and safe use of medicines: real life and applied research","author":"F Hou\u00ffez","year":"2020","unstructured":"Hou\u00ffez F. From passive to active: patients as contributors to medicinal product risk communication research. In: Bahri P, editor. Communicating about risks and safe use of medicines: real life and applied research. Singapore: Springer; 2020. p. 457\u201380."},{"key":"1285_CR113","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/978-981-15-3013-5_14","volume-title":"Communicating about risks and safe use of medicines: real life and applied research","author":"HG Leufkens","year":"2020","unstructured":"Leufkens HG. Pharmacoepidemiology. In: Bahri P, editor. Communicating about risks and safe use of medicines: real life and applied research. Singapore: Springer; 2020. p. 415\u201332."},{"key":"1285_CR114","first-page":"481","volume-title":"Communicating about risks and safe use of medicines: real life and applied research","author":"NA Kshirsagar","year":"2020","unstructured":"Kshirsagar NA. Afterword: the dimension of communicating medicine risks in low- and middle-income countries. In: Bahri P, editor. Communicating about risks and safe use of medicines: real life and applied research. Singapore: Springer; 2020. p. 481\u20134."},{"key":"1285_CR115","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/978-981-15-3013-5_9","volume-title":"Communicating about risks and safe use of medicines: real life and applied research","author":"M M\u00f8lleb\u00e6k","year":"2020","unstructured":"M\u00f8lleb\u00e6k M. Rhetoric and science and technology studies. In: Bahri P, editor. Communicating about risks and safe use of medicines: real life and applied research. Singapore: Springer; 2020. p. 267\u201384."},{"key":"1285_CR116","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/978-981-15-3013-5_13","volume-title":"Communicating about risks and safe use of medicines: real life and applied research","author":"EH Morrato","year":"2020","unstructured":"Morrato EH, Smith MY. Dissemination and implementation science. In: Bahri P, editor. Communicating about risks and safe use of medicines: real life and applied research. Singapore: Springer; 2020. p. 385\u2013413."},{"key":"1285_CR117","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/978-981-15-3013-5_10","volume-title":"Communicating about risks and safe use of medicines: real life and applied research","author":"GJ Nowak","year":"2020","unstructured":"Nowak GJ, Cacciatore MA. Media science and practice. In: Bahri P, editor. Communicating about risks and safe use of medicines: real life and applied research. Singapore: Springer; 2020. p. 285\u2013305."},{"key":"1285_CR118","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/978-981-15-3013-5_7","volume-title":"Communicating about risks and safe use of medicines: real life and applied research","author":"S Rubinelli","year":"2020","unstructured":"Rubinelli S, Diviani N, Fiordelli M. The cognitive and behavioural sciences. In: Bahri P, editor. Communicating about risks and safe use of medicines: real life and applied research. Singapore: Springer Nature; 2020. p. 195\u2013217."},{"key":"1285_CR119","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/978-981-15-3013-5_15","volume-title":"Communicating about risks and safe use of medicines: real life and applied research","author":"B Str\u00e4ter","year":"2020","unstructured":"Str\u00e4ter B. Legal frameworks. In: Bahri P, editor. Communicating about risks and safe use of medicines: real life and applied research. Singapore: Springer; 2020. p. 433\u201355."},{"key":"1285_CR120","doi-asserted-by":"crossref","unstructured":"Taylor BJ, SA Moorhead. The social sciences. In: Bahri P, editor. Communicating about risks and safe use of medicines: real life and applied research. Singapore: Springer; 2020. pp. 219\u201365.","DOI":"10.1007\/978-981-15-3013-5_8"},{"key":"1285_CR121","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/978-981-15-3013-5_6","volume-title":"Communicating about risks and safe use of medicines: real life and applied research","author":"G van Thiel","year":"2020","unstructured":"van Thiel G. Ethical framework. In: Bahri P, editor. Communicating about risks and safe use of medicines: real life and applied research. Singapore: Springer; 2020. p. 181\u201393."},{"key":"1285_CR122","unstructured":"NEJM Catalyst. Patients and consumers in 2030 [webinar]. 2021."},{"key":"1285_CR123","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i2926","volume":"353","author":"JK Aronson","year":"2016","unstructured":"Aronson JK. \"Collaborative care\" is preferable to \"patient centred care\". BMJ. 2016;353:i2926.","journal-title":"BMJ"},{"key":"1285_CR124","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s00228-019-02705-1","volume":"75","author":"P Brown","year":"2019","unstructured":"Brown P, Bahri P. \u2018Engagement\u2019 of patients and healthcare professionals in regulatory pharmacovigilance: establishing a conceptual and methodological framework. Eur J Clin Pharmacol. 2019;75:1181\u201392.","journal-title":"Eur J Clin Pharmacol"},{"key":"1285_CR125","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s40264-021-01111-w","volume":"44","author":"P Bahri","year":"2021","unstructured":"Bahri P, Pariente A. Systematising pharmacovigilance engagement of patients, healthcare professionals and regulators\u2014a practical decision-guide derived from the International Risk Governance Framework for engagement events and discourse. Drug Saf. 2021;44:1193\u2013208.","journal-title":"Drug Saf"},{"key":"1285_CR126","doi-asserted-by":"publisher","DOI":"10.15252\/embr.202153182","volume":"22","author":"G-F B\u00f6l","year":"2021","unstructured":"B\u00f6l G-F. The COVID-19 pandemic: agile versus blundering communication during a worldwide crisis. EMBO Rep. 2021;22: e53182.","journal-title":"EMBO Rep"},{"key":"1285_CR127","doi-asserted-by":"publisher","DOI":"10.1057\/9780230503946","volume-title":"Risk management in post-trust societies","author":"RE L\u00f6fstedt","year":"2005","unstructured":"L\u00f6fstedt RE. Risk management in post-trust societies. Houndmills: Palgrave Macmillan; 2005."},{"key":"1285_CR128","unstructured":"National Academies of Sciences, Engineering, and Medicine. Does the public trust science? Trust and confidence at the intersections of the life sciences and society [workshop summary]. Washington, DC: The National Academies Press; 2015."},{"key":"1285_CR129","volume-title":"Overcoming biopharma\u2019s trust deficit","author":"G Reh","year":"2021","unstructured":"Reh G, Ronte H, Gupta L, Varia H. Overcoming biopharma\u2019s trust deficit. New York: Deloitte Center for Health Solutions; 2021."},{"key":"1285_CR130","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40264-016-0466-1","volume":"40","author":"D Way","year":"2017","unstructured":"Way D, Blazsin H, L\u00f6fstedt R, Bouder F. Pharmaceutical benefit-risk communication tools: a review of the literature. Drug Saf. 2017;40:15\u201336.","journal-title":"Drug Saf"},{"key":"1285_CR131","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1177\/0272989X07306786","volume":"27","author":"LM Schwartz","year":"2007","unstructured":"Schwartz LM, Woloshin S, Welch HG. The drug facts box: providing consumers with simple tabular data on drug benefit and harm. Med Decis Mak. 2007;27:655\u201362.","journal-title":"Med Decis Mak"},{"key":"1285_CR132","doi-asserted-by":"publisher","first-page":"516","DOI":"10.7326\/0003-4819-150-8-200904210-00106","volume":"150","author":"LM Schwartz","year":"2009","unstructured":"Schwartz LM, Woloshin S, Welch HG. Using a drug facts box to communicate drug benefits and harms: two randomized trials. Ann Intern Med. 2009;150:516\u201327.","journal-title":"Ann Intern Med"},{"key":"1285_CR133","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1037\/a0014474","volume":"28","author":"M Galesic","year":"2009","unstructured":"Galesic M, Garcia-Retamero R, Gigerenzer G. Using icon arrays to communicate medical risks: overcoming low numeracy. Health Psychol. 2009;28:210\u20136.","journal-title":"Health Psychol"},{"issue":"Suppl. 2","key":"1285_CR134","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1186\/1472-6947-13-S2-S7","volume":"13","author":"LJ Trevena","year":"2013","unstructured":"Trevena LJ, Zikmund-Fisher BJ, Edwards A, Gaissmaier W, Galesic M, Han PKJ, et al. Presenting quantitative information about decision outcomes: a risk communication primer for patient decision aid developers. BMC Med Inform Decis Mak. 2013;13(Suppl. 2):S7.","journal-title":"BMC Med Inform Decis Mak"},{"key":"1285_CR135","unstructured":"Bahri P. Infographics, pictograms, and visualised risk estimates for pharmacovigilance: between demand and evidence [presentation]. In: 20th annual meeting of the International Society of Pharmacovigilance (ISoP) in Muscat, 9 November 2021."},{"key":"1285_CR136","unstructured":"World Health Organization (WHO). The impact of COVID-19 on global health goals. Geneva: WHO; 2021. https:\/\/www.who.int\/news-room\/spotlight\/the-impact-of-covid-19-on-global-health-goals. Accessed 13 Mar 2022."},{"key":"1285_CR137","unstructured":"United Nations Development Programme (UNDP). COVID-19: the socio-economic impact. New York: UNDP; 2022. https:\/\/www.undp.org\/coronavirus\/socio-economic-impact-covid-19. Accessed 13 Mar 2022."},{"key":"1285_CR138","unstructured":"Rothkopf DJ. SARS also spurs an \u2018information epidemic\u2019.\u00a0Newsday. 2003. https:\/\/www.proquest.com\/docview\/279705520. Accessed 29 May 2022."},{"key":"1285_CR139","unstructured":"World Health Organization (WHO). Joint statement by WHO, UN, UNICEF, UNDP, UNESCO, UNAIDS, ITU, UN global pulse, and IFRC. Managing the COVID-19 infodemic: promoting healthy behaviours and mitigating the harm from misinformation and disinformation. Geneva: WHO; 2020. https:\/\/www.who.int\/news\/item\/23-09-2020-managing-the-covid-19-infodemic-promoting-healthy-behaviours-and-mitigating-the-harm-from-misinformation-and-disinformation#:~:text=An%20infodemic%20is%20an%20overabundance%20of%20information%2C%20both,and%20advance%20alternative%20agendas%20of%20groups%20or%20individuals. Accessed 13 May 2021."},{"key":"1285_CR140","unstructured":"\"infodemic, n.\" OED Online, Oxford University Press; 2022. http:\/\/www.oed.com\/view\/Entry\/88407009. Accessed 11 Sept 2022."},{"key":"1285_CR141","unstructured":"United Nations Children\u2019s Fund (UNICEF). Vaccine misinformation management field guide. UNICEF: New York; 2020."},{"key":"1285_CR142","doi-asserted-by":"publisher","first-page":"16598","DOI":"10.1038\/s41598-020-73510-5","volume":"10","author":"M Cinelli","year":"2020","unstructured":"Cinelli M, Quattrociocchi W, Galeazzi A, Valensise CM, Brugnoli E, Schmidt AL, Zola P, Zollo F, Scala A. The COVID-19 social media infodemic. Sci Rep. 2020;10:16598.","journal-title":"Sci Rep"},{"key":"1285_CR143","doi-asserted-by":"publisher","DOI":"10.2196\/35552","volume":"24","author":"MA Gisondi","year":"2022","unstructured":"Gisondi MA, Barber R, Faust JS, Raja A, Strehlow MC, Westafer LM, Gottlieb M. A deadly infodemic: social media and the power of COVID-19 misinformation. J Med Internet Res. 2022;24: e35552.","journal-title":"J Med Internet Res"},{"key":"1285_CR144","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1093\/mind\/fzx042","volume":"128","author":"N Ballantyne","year":"2019","unstructured":"Ballantyne N. Epistemic trespassing. Mind. 2019;128:367\u201395.","journal-title":"Mind"},{"key":"1285_CR145","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1093\/ije\/dyab128","volume":"50","author":"MY Smith","year":"2021","unstructured":"Smith MY, Bahri P, Gaudino JA Jr, Moreira RS, Danyluk GM, Palevsky SL. The role of epidemiologists in communicating SARS-CoV-2 evidence: a call for adopting epidemiological literacy standards. Intern J Epidemiol. 2021;50:1410\u20135 (Epub 28 June 2021).","journal-title":"Intern J Epidemiol."},{"key":"1285_CR146","volume-title":"Better doctors, better patients, better decisions: envisioning health care 2020","year":"2011","unstructured":"Gigerenzer G, Gray JAM, editors. Better doctors, better patients, better decisions: envisioning health care 2020. Boston: MIT Press; 2011."},{"key":"1285_CR147","volume-title":"Health literacy: improving health, health systems, and health policy around the world [workshop summary]","author":"Institute of Medicine","year":"2013","unstructured":"Institute of Medicine. Health literacy: improving health, health systems, and health policy around the world [workshop summary]. Washington, DC: The National Academies Press; 2013."},{"key":"1285_CR148","volume-title":"Characterizing and communicating uncertainty in the assessment of benefits and risks of pharmaceutical products: workshop summary","author":"Institute of Medicine","year":"2014","unstructured":"Institute of Medicine. Characterizing and communicating uncertainty in the assessment of benefits and risks of pharmaceutical products: workshop summary. Washington, DC: The National Academies Press; 2014."},{"issue":"10","key":"1285_CR149","doi-asserted-by":"publisher","first-page":"781","DOI":"10.7326\/0003-4819-141-10-200411160-00009","volume":"141","author":"JP Ioannidis","year":"2004","unstructured":"Ioannidis JP, Evans SJ, Gotzsche PC, O\u2019Neill RT, Altman DG, Schulz K, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Annu Intern Med. 2004;141(10):781\u20138.","journal-title":"Annu Intern Med."},{"key":"1285_CR150","unstructured":"Slovic P. The feeling of risk: new perspectives on risk perception. London, Washington DC: Earthscan, 2010."},{"key":"1285_CR151","volume-title":"Risk communication: a mental models approach","author":"MG Morgan","year":"2002","unstructured":"Morgan MG, Fischhoff B, Bostrom A, Atman CJ. Risk communication: a mental models approach. Cambridge: Cambridge University Press; 2002."},{"key":"1285_CR152","first-page":"459","volume":"109","author":"W H\u00e4user","year":"2012","unstructured":"H\u00e4user W, Hansen E, Enck P. Nocebo phenomena in medicine: their relevance in everyday clinical practice. Dtsch Arztebl Int. 2012;109:459\u201365.","journal-title":"Dtsch Arztebl Int"},{"key":"1285_CR153","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s40290-020-00367-4","volume":"34","author":"G Furlan","year":"2020","unstructured":"Furlan G, Power D. The unintended consequences of adverse event information on medicines\u2019 risks and label content. Pharm Med. 2020;34:369\u201380.","journal-title":"Pharm Med."},{"key":"1285_CR154","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.43955","volume":"5","author":"JW Haas","year":"2022","unstructured":"Haas JW, Bender FL, Ballou S, Kelley JM, Wilhelm M, Miller FG, Rief W, Kaptchuk TJ. Frequency of adverse events in the placebo arms of COVID-19 vaccine trials: a systematic review and meta-analysis. JAMA Netw Open. 2022;5: e2143955.","journal-title":"JAMA Netw Open"},{"key":"1285_CR155","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1016\/j.vaccine.2014.01.081","volume":"32","author":"HJ Larson","year":"2014","unstructured":"Larson HJ, Jarrett C, Eckersberger E, Smith DMD, Paterson P. Understanding vaccine hesitancy around vaccines and vaccination from a global perspective: a systematic review of published literature, 2007\u20132012. Vaccine. 2014;32:2150\u20139.","journal-title":"Vaccine"},{"key":"1285_CR156","unstructured":"van Hunsel. Signals from a national spontaneous reporting system: what regulatory action do they lead to? [presentation]. DIA Global; 2020."},{"key":"1285_CR157","unstructured":"Genov G, Bahri P, Zaccaria C. Pharmacovigilance for COVID-19 vaccines: prospects and plans for 2022 [presentation]. European Medicines Agency Patient and Consumers\u2019 and Healthcare Professionals\u2019 Working Parties joint meeting. Amsterdam; 2\u20133 March 2022. https:\/\/www.ema.europa.eu\/en\/documents\/presentation\/presentation-pharmacovigilance-covid-19-vaccines-prospects-plans-2022-ggenov-pbahri-czaccaria-ema_en.pdf. Accessed 27 Apr 2022."},{"key":"1285_CR158","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/1475-2875-10-230","volume":"10","author":"AA Adedeji","year":"2011","unstructured":"Adedeji AA, Sanusi B, Tella A, Akinsanya M, Ojo O, Akinwunmi MO, Tikare OA, Ogunwande IA, Ogundahunsi OA, Ayilara OO, Ademola TT, Fehintola FA, Ogundahunsi OAT. Exposure to anti-malarial drugs and monitoring of adverse drug reactions using toll-free mobile phone calls in private retail sector in Sagamu, Nigeria: implications for pharmacovigilance. Malar J. 2011;10:230.","journal-title":"Malar J"},{"key":"1285_CR159","doi-asserted-by":"publisher","DOI":"10.5210\/ojphi.v6i2.5368","volume":"6","author":"PI Machingura","year":"2014","unstructured":"Machingura PI, Adekola O, Mueni E, Oaiya O, Gustafsson LL, Heller RF. Perceived value of applying information communication technology to implement guidelines in developing countries; an online questionnaire study among public health workers. Online J Public Health Inform. 2014;6: e180.","journal-title":"Online J Public Health Inform."},{"key":"1285_CR160","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/1472-6947-14-78","volume":"14","author":"J Nilseng","year":"2014","unstructured":"Nilseng J, Gustafsson LL, Nungu A, Bastholm-Rahmner P, Mazali D, Pehrson B, Eriksen J. A cross-sectional pilot study assessing needs and attitudes to implementation of information and communication technology for rational use of medicines among healthcare staff in rural Tanzania. BMC Med Inform Decis Mak. 2014;14:78.","journal-title":"BMC Med Inform Decis Mak"},{"key":"1285_CR161","unstructured":"Gigerenzer G, Todd PM, and the ABC Research Group. Simple heuristics that make us smart. New York: Oxford University Press; 1999."},{"key":"1285_CR162","doi-asserted-by":"crossref","unstructured":"Todd PM, Gigerenzer G, and the ABC Research Group. Ecological rationality: intelligence in the world. New York: Oxford University Press; 2012.","DOI":"10.1093\/acprof:oso\/9780195315448.003.0011"},{"key":"1285_CR163","volume-title":"Pharmacoepidemiology","author":"BL Strom","year":"2005","unstructured":"Strom BL. Pharmacoepidemiology. 4th ed. Chichester: Wiley; 2005.","edition":"4"},{"key":"1285_CR164","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s11023-015-9367-9","volume":"26","author":"T Gr\u00fcne-Yano","year":"2016","unstructured":"Gr\u00fcne-Yano T, Hertwig R. Nudge versus boost: how coherent are policy and theory? Mind Mach. 2016;26:149\u201383.","journal-title":"Mind Mach"},{"key":"1285_CR165","unstructured":"21st Annual Meeting of the International Society of Pharmacovigilance (ISoP). Conference programme. Verona: 20\u201323 September 2022. https:\/\/www.isop2022verona.org. Accessed 27 Apr 2022."},{"key":"1285_CR166","first-page":"1129","volume":"45","author":"K Hartigan-Go","year":"2022","unstructured":"Hartigan-Go K. When public health and politics clash: communicating about Dengvaxia between science and emotions [conference abstract]. Drug Saf. 2022;45:1129 (abstract\u00a0O-026).","journal-title":"Drug Saf"},{"key":"1285_CR167","unstructured":"Kant A, Tuccori M. How do local contexts relate to public health communication? Communicating about COVID-19 vaccines in Italy and the Netherlands [presentation]. In: 21th annual meeting of the International Society of Pharmacovigilance (ISoP). Verona: 20\u201323 September 2022."},{"issue":"5","key":"1285_CR168","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.sapharm.2013.02.007","volume":"9","author":"DK Raynor","year":"2013","unstructured":"Raynor DK. User testing in developing patient medication information in Europe. Res Soc Adm Pharm. 2013;9(5):640\u20135.","journal-title":"Res Soc Adm Pharm"},{"key":"1285_CR169","doi-asserted-by":"crossref","unstructured":"Raynor DK, Blenkinsopp A, Knapp P, Grime J, Nicolson DJ, Pollock K, Dorer G, Gilbody S, Dickinson D, Maule AJ, Spoor P. A systematic review of quantitative and qualitative research on role and effectiveness of written information available to patients about individual medicines. Health Technol Assess. 2007;11:iii (1\u2013160).","DOI":"10.3310\/hta11050"},{"key":"1285_CR170","doi-asserted-by":"crossref","unstructured":"Dickinson R, DK Raynor, Knapp P, MacDonald J. Providing additional information about the benefits of statins in a leaflet for patients with coronary heart disease: a qualitative study of the impact on attitudes and beliefs. BMJ Open. 2016;6(12):e012000 (published online 2 Dec 2016).","DOI":"10.1136\/bmjopen-2016-012000"},{"key":"1285_CR171","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0020042","volume":"2","author":"A Herxheimer","year":"2005","unstructured":"Herxheimer A. Communicating with patients about harms and risks. PLoS Med. 2005;2: e42.","journal-title":"PLoS Med"},{"key":"1285_CR172","first-page":"616","volume":"290","author":"DK Raynor","year":"2013","unstructured":"Raynor DK. The benefits of medicines outweigh the risks of treatment\u2014says who? Pharm J. 2013;290:616\u20137.","journal-title":"Pharm J"},{"key":"1285_CR173","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1037\/0033-295X.102.4.684","volume":"102","author":"G Gigerenzer","year":"1995","unstructured":"Gigerenzer G, Hoffrage U. How to improve Bayesian reasoning without instruction: frequency formats. Psychol Rev. 1995;102:684\u2013704.","journal-title":"Psychol Rev"},{"key":"1285_CR174","volume-title":"Risk savvy: how to make good decisions","author":"G Gigerenzer","year":"2014","unstructured":"Gigerenzer G. Risk savvy: how to make good decisions. New York: Penguin; 2014."},{"key":"1285_CR175","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/978-94-007-1433-5_24","volume-title":"Hand book of risk theory: epistemology, decision theory, ethics, and social amplification of risk","author":"N Bodemer","year":"2012","unstructured":"Bodemer N, Gaissmaier W. Risk communication in health. In: Roeser S, Hillerbrand R, Sandin P, Peterson M, editors. Hand book of risk theory: epistemology, decision theory, ethics, and social amplification of risk. Dordrecht: Springer; 2012. p. 621\u201360."},{"key":"1285_CR176","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1093\/jnci\/93.14.1109","volume":"93","author":"A Shibata","year":"2001","unstructured":"Shibata A, Whittemore AS. Re: Prostate cancer incidence and mortality in the United States and the United Kingdom. J Naty Canc Inst. 2001;93:1109\u201310.","journal-title":"J Naty Canc Inst."},{"key":"1285_CR177","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.1001\/jama.283.22.2975","volume":"283","author":"HG Welch","year":"2000","unstructured":"Welch HG, Schwartz LM, Woloshin S. Are increasing 5-year survival rates evidence of success against cancer? J Am Med Assoc. 2000;283:2975\u20138.","journal-title":"J Am Med Assoc"},{"key":"1285_CR178","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s40264-013-0079-x","volume":"36","author":"S Piening","year":"2013","unstructured":"Piening S, de Graeff PA, Straus SMJM, Haaijer-Ruskamp FM, Mol PGM. The additional value of an e-mail to inform healthcare professionals of a drug safety issue: a randomized controlled trial in the Netherlands. Drug Saf. 2013;36:723\u201331.","journal-title":"Drug Saf"},{"key":"1285_CR179","doi-asserted-by":"crossref","unstructured":"Reber KC, Piening S, Wieringa JE, Straus SMJM, Raine JM, de Graeff PA, Haaijer-Ruskamp FM, Mol PGM. When direct health-care professional communications have an impact on inappropriate and unsafe use of medicines. Clin Pharmacol Ther. 203;93:360\u20135.","DOI":"10.1038\/clpt.2012.262"},{"key":"1285_CR180","unstructured":"Tadin J, Macoli\u0107 \u0160arini\u0107 V. Communicating safety issues: the Croatian experience. Uppsala Rep. 2012;57:15."},{"key":"1285_CR181","unstructured":"Theatre group \u2018Mala Scena\u2019. http:\/\/www.mala-scena.hr. Accessed 19 Sept 2020."},{"key":"1285_CR182","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.vascn.2016.04.011","volume":"81","author":"MI Geer","year":"2016","unstructured":"Geer MI, Shah PA, Tanki SA, Shah MY. Frequency types, severity, preventability and costs of adverse drug reactions at a tertiary care hospital. J Pharmacol Toxicol Methods. 2016;81:323\u201334.","journal-title":"J Pharmacol Toxicol Methods"},{"key":"1285_CR183","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1007\/s40264-019-00860-z","volume":"42","author":"J Sultana","year":"2019","unstructured":"Sultana J, Fontana A, Giorgianni F, Tillati S, Cricelli C, Pasqua A, Patorno E, Ballard C, Sturkenboom M, Trifir\u00f2 G. Measuring the effectiveness of safety warnings on the risk of stroke in older antipsychotic users: a nationwide cohort study in two large electronic medical records databases in the United Kingdom and Italy. Drug Saf. 2019;42:1471\u201385.","journal-title":"Drug Saf"},{"key":"1285_CR184","unstructured":"Aronson JK. The Bengt Erik Wiholm Lecture 2017: the language of pharmacovigilance [conference abstract]. Drug Saf. 2017;40:1037 (abstract 273)."},{"key":"1285_CR185","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1007\/s40264-022-01223-x","volume":"45","author":"JK Aronson","year":"2022","unstructured":"Aronson JK. Lost in translation: a multilingual survey of interlinguistic variations in terms used in pharmacovigilance. Drug Saf. 2022;45:1363\u20138.","journal-title":"Drug Saf"},{"key":"1285_CR186","unstructured":"The importance of communication in pharmacovigilance [session sponsored by the ISoP CommSIG]. In: Conference programme. Bogot\u00e1: 19th annual meeting of the International Society of Pharmacovigilance; 26\u201329 October 2019."},{"key":"1285_CR187","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1111\/j.1365-2125.2005.02440.x","volume":"60","author":"RE Ferner","year":"2005","unstructured":"Ferner RE, Coleman J, Pirmohamed M, Constable SA, Rouse A. The quality of information on monitoring for haematological adverse drug reactions. Br J Clin Pharmacol. 2005;60:448\u201351.","journal-title":"Br J Clin Pharmacol"},{"key":"1285_CR188","first-page":"1352","volume":"50","author":"AFJ Geerts","year":"2012","unstructured":"Geerts AFJ, De Koning FHP, Van Solinge WW, De Smet PA, Egberts TC. Instructions on laboratory monitoring in 200 drug labels. Clin Lab Med. 2012;50:1352\u20138.","journal-title":"Clin Lab Med"},{"key":"1285_CR189","unstructured":"20th Annual Meeting of the International Society of Pharmacovigilance (ISoP). In: Conference programme. Muscat: 8\u201310 November 2021. https:\/\/www.isop2021oman.org. Accessed 12 Feb 2022."},{"key":"1285_CR190","unstructured":"Foundation for Education and Research of the International Pharmaceutical Federation (FIP). FIP Pictograms Software (webpage). Den Haag: FIP; 2017. https:\/\/www.fipfoundation.org\/pictograms-support\/pictogram-software\/. Accessed 13 Mar 2022."},{"key":"1285_CR191","unstructured":"Agence nationale\u00a0de s\u00e9curit\u00e9 du m\u00e9dicament\u00a0et des produits de sant\u00e9 (ANSM). A l\u2019attention des titulaires d\u2019AMM, concernant l\u2019apposition du \"pictogramme femmes enceintes\u201d. Saint-Denis: ANSM; 2018. https:\/\/ansm.sante.fr\/uploads\/2021\/02\/10\/qr-picto-grossesse-septembre-2018-1.pdf. Accessed 13 Mar 2022."},{"key":"1285_CR192","unstructured":"European Medicines Agency (EMA). Combined hormonal contraceptives (webpage). London: EMA; 2013. https:\/\/www.ema.europa.eu\/en\/human-regulatory\/post-authorisation\/referral-procedures\/combined-hormonal-contraceptives\/. Accessed 13 Mar 2022."},{"key":"1285_CR193","unstructured":"Data Leads. About us. New Delhi: Data Leads; 2021. https:\/\/dataleads.co.in\/about-us. Accessed 13 Mar 2022."},{"key":"1285_CR194","first-page":"874","volume":"37","author":"D Darko","year":"2014","unstructured":"Darko D, Sabblah G, Amponsa-Achiano K, Antwi-Agyei KO. The value of patient reporting in signal generation. Drug Saf. 2014;37:874 (abstract\u00a0P-086).","journal-title":"Drug Saf"},{"key":"1285_CR195","first-page":"842","volume":"37","author":"C Anton","year":"2014","unstructured":"Anton C, Cox AR, Ferner RE. Regulatory action; medical inaction? Drug Saf. 2014;37:842 (abstract\u00a0P-020).","journal-title":"Drug Saf"},{"key":"1285_CR196","first-page":"883","volume":"37","author":"ST Tomczyk","year":"2014","unstructured":"Tomczyk ST. How the transparency data regulations are changing the communication regarding benefit-risk of medications. Drug Saf. 2014;37:883 (abstract\u00a0P-103).","journal-title":"Drug Saf"},{"key":"1285_CR197","first-page":"968","volume":"38","author":"MA Balazs","year":"2015","unstructured":"Balazs MA, Piko B. Do We need pharmacovigilance education and do adolescents have adequate knowledge regarding proper medicine use? Drug Saf. 2015;38:968 (abstract\u00a0P017).","journal-title":"Drug Saf"},{"key":"1285_CR198","first-page":"998","volume":"38","author":"H Lebanova","year":"2015","unstructured":"Lebanova H, Kalaijiev K, Getov I. Educational materials can have positive impact on patients\u2019 knowledge of ADRs: a randomized controlled trial of novel educational booklet. Drug Saf. 2015;38:998 (abstract\u00a0P087).","journal-title":"Drug Saf"},{"key":"1285_CR199","first-page":"1015","volume":"38","author":"D Azzarello","year":"2015","unstructured":"Azzarello D, Marinac B, Bwire R, O\u2019Reilly A. Standardized messaging on product packaging as a mechanism to mitigate potential risks of medicinal products with known teratogenicity. Drug Saf. 2015;38:1015 (abstract\u00a0P125).","journal-title":"Drug Saf"},{"key":"1285_CR200","first-page":"1037","volume":"38","author":"F Varallo","year":"2015","unstructured":"Varallo F, Planeta C, Mastroianni P. Impact of pharmacovigilance multifaceted educational intervention on knowledge, skills and attitudes of a multidisciplinary healthcare team. Drug Saf. 2015;38:1037 (abstract\u00a0P172).","journal-title":"Drug Saf"},{"key":"1285_CR201","first-page":"1011","volume":"39","author":"K Vishnu","year":"2016","unstructured":"Vishnu K, Mamatha KR, Jayanthi CR. Knowledge, attitude and practice towards pharmacovigilance and adverse drug reaction reporting among postgraduate medical students. Drug Saf. 2016;39:1011 (abstract\u00a0P042).","journal-title":"Drug Saf"},{"key":"1285_CR202","first-page":"1025","volume":"40","author":"M Jadeja","year":"2017","unstructured":"Jadeja M. Evaluation of the first EU-wide social media ADR awareness week: 7\u201311 November 2016. Drug Saf. 2017;40:1025 (abstract\u00a0236).","journal-title":"Drug Saf"},{"key":"1285_CR203","first-page":"941","volume":"40","author":"JL Montastruc","year":"2017","unstructured":"Montastruc JL, Damase-Michel C, Lacroix I, Durrieu G, Montastruc F, Sommet A, BagherI H. Drugs, adverse drug reactions and pharmacovigilance in the adventures of Tintin. Drug Saf. 2017;40:941 (abstract\u00a08).","journal-title":"Drug Saf"},{"key":"1285_CR204","first-page":"945","volume":"40","author":"B Hugman","year":"2017","unstructured":"Hugman B. Alternative facts: why patient safety is under threat and what we can do about it. Drug Saf. 2017;40:945 (abstract\u00a021).","journal-title":"Drug Saf"},{"key":"1285_CR205","first-page":"1009","volume":"40","author":"O Pinar","year":"2017","unstructured":"Pinar O, Guresci N, Unal B. Impact of internet and social media use in pharmacovigilance. Drug Saf. 2017;40:1009 (abstract\u00a0189).","journal-title":"Drug Saf"},{"key":"1285_CR206","first-page":"1040","volume":"40","author":"S Maskell","year":"2017","unstructured":"Maskell S. When does social media add value to pharmacovigilance? Drug Saf. 2017;40:1040 (abstract\u00a0280).","journal-title":"Drug Saf"},{"key":"1285_CR207","first-page":"1162","volume":"41","author":"H Dominicus","year":"2018","unstructured":"Dominicus H, Doua J, Verstraeten T. Online availability of regulatory documents, safety information and adverse drug reaction reporting in African countries. Drug Saf. 2018;41:1162 (abstract\u00a0ISoP18-1161).","journal-title":"Drug Saf"},{"key":"1285_CR208","first-page":"1149","volume":"41","author":"G Castillon","year":"2018","unstructured":"Castillon G, Gesztesi Z, Moride Y. Product confusion errors: a pharmacovigilance analysis of VigibaseTM and Canada Vigilance case narratives. Drug Saf. 2018;41:1149 (abstract\u00a0ISoP18-1132).","journal-title":"Drug Saf"},{"key":"1285_CR209","first-page":"1186","volume":"41","author":"HV Lebanova","year":"2018","unstructured":"Lebanova HV, Staynova R, Getova V. Pharmacists\u2019 role in risk communication on self-medication: pilot study from Bulgaria. Drug Saf. 2018;41:1186 (abstract\u00a0ISoP18-1227).","journal-title":"Drug Saf"},{"key":"1285_CR210","first-page":"1244","volume":"41","author":"H Attjioui","year":"2018","unstructured":"Attjioui H, Boutayeb S, Errihani H, Aliat Z, Soulaymani R, Tebaa A, Meddah B. Role of patient information on the adverse effects of medicines in oncology. Drug Saf. 2018;41:1244 (abstract\u00a0ISoP18-1439).","journal-title":"Drug Saf"},{"key":"1285_CR211","first-page":"1199","volume":"41","author":"KY Hartigan-Go","year":"2018","unstructured":"Hartigan-Go KY, Larson H. What is risky about risk communications: a case study on dengue vaccine. Drug Saf. 2018;41:1199 (abstract\u00a0ISoP18-1276).","journal-title":"Drug Saf"},{"key":"1285_CR212","first-page":"1159","volume":"41","author":"BPJ Hugman","year":"2018","unstructured":"Hugman BPJ. Amusing ourselves to death: how science and reason are losing their grip in public discourse. Drug Saf. 2018;41:1159 (abstract\u00a0ISoP18-1154).","journal-title":"Drug Saf"},{"key":"1285_CR213","first-page":"1163","volume":"41","author":"A Hoegberg","year":"2018","unstructured":"Hoegberg A. Social media: the battleground for public opinion on medicines safety. Drug Saf. 2018;41:1163 (abstract\u00a0ISoP18-1165).","journal-title":"Drug Saf"},{"key":"1285_CR214","first-page":"1233","volume":"42","author":"R Soulaymani","year":"2019","unstructured":"Soulaymani R, Sefiani H, Benabdallah G, Tebaa A. Promoting spontaneous adverse event reporting in Morocco: the national reporting day. Drug Saf. 2019;42:1233 (abstract\u00a054).","journal-title":"Drug Saf"},{"key":"1285_CR215","first-page":"1216","volume":"42","author":"A Shah","year":"2019","unstructured":"Shah A, Corrado A, Mingle E, O\u2019Shea L, Wagman L, Di Menno R, Mockute R, Beauchamp S, Freeman J, Abatemarco D. Communicating the value of pharmacovigilance, above and beyond compliance. Drug Saf. 2019;42:1216 (abstract\u00a021).","journal-title":"Drug Saf"},{"key":"1285_CR216","first-page":"1220","volume":"42","author":"M Forstner","year":"2019","unstructured":"Forstner M. digital tools for the communication of risk minimization measures for medicines. Drug Saf. 2019;42:1220 (abstract\u00a029).","journal-title":"Drug Saf"},{"key":"1285_CR217","first-page":"1227","volume":"42","author":"ML Chan-Liston","year":"2019","unstructured":"Chan-Liston ML, Mai DLH, Bourke J, McWilliams R, Berry T, Sheehan P, Freeman J. Evolution of communication plan REMS programs. Drug Saf. 2019;42:1227 (abstract\u00a041).","journal-title":"Drug Saf"},{"key":"1285_CR218","first-page":"1234","volume":"42","author":"S Adjaude","year":"2019","unstructured":"Adjaude S, Varallo F, Pererira L, Lopes J. Use of social media in pharmacovigilance for patient empowerment and spontaneous reporting: a systematic review. Drug Saf. 2019;42:1234 (abstract\u00a056).","journal-title":"Drug Saf"},{"key":"1285_CR219","unstructured":"CarvalhoI D, Consani de Siqueira B, Rafaini Lloret G, Miguez de Almeida I. Identification of communication opportunities in the report process of adverse reactions. Drug Saf. 2019;42:1235 (abstract 58)."},{"key":"1285_CR220","first-page":"1241","volume":"42","author":"A Duarte","year":"2019","unstructured":"Duarte A, Roque F, Roque V, Herdeiro M. How Portuguese users of social media communicate with pharmacovigilance unit Facebook pages? Drug Saf. 2019;42:1241 (abstract\u00a070).","journal-title":"Drug Saf"},{"key":"1285_CR221","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s40264-018-0737-0","volume":"42","author":"I Convertino","year":"2019","unstructured":"Convertino I, Leonardi L, Tuccori M, Ferraro S, Blandizzi C. Listening social media for pharmacovigilance objectives: which usefulness? Drug Saf. 2019;42:1245 (abstract\u00a078).","journal-title":"Drug Saf"},{"key":"1285_CR222","first-page":"1254","volume":"42","author":"AJ Saavedra Espitia","year":"2019","unstructured":"Saavedra Espitia AJ, Ospina FL. Patients\u2019 knowledge of ADR and its notification in Colombia: a quantitative study. Drug Saf. 2019;42:1254 (abstract\u00a093).","journal-title":"Drug Saf"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-023-01285-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-023-01285-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-023-01285-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T11:16:11Z","timestamp":1744715771000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-023-01285-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,23]]},"references-count":222,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["1285"],"URL":"https:\/\/doi.org\/10.1007\/s40264-023-01285-5","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,23]]},"assertion":[{"value":"1 March 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No sources of funding were used in the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The views expressed in this report are the authors\u2019 personal views and may not be understood or quoted as being made on behalf of or reflecting the position of the employing organisations. Priya Bahri\u2019s activity as the ISoP CommSIG Coordinator is pro bono in her personal capacity and time, outside the working hours of the European Medicines Agency as her employing organisation. She abstains from contributing to ISoP comments in response to public consultations of EU policies and projects.Priya Bahri, Geoffrey Bowring, Brian D. Edwards, Angela Caro-Rojas, Bruce P.J. Hugman, Peter G. Mol, Katarina Ilic, Riadh Daghfous, Irene Fermont, Wolfgang Gaissmaier, Mohammad Ishaq Geer, Fran\u00e7ois Hou\u00ffez, Hansj\u00f6rg Neth, Gediminas Norgela, Yaowares Oppamayun, Mehdi Bouhlel, Federica Santoro and Janet Sultana have no conflicts of interests to declare. Christopher Anton receives an annual grant from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) and owns shares in AstraZeneca, GlaxoSmithKline, BioNTech, Smith and Nephew, and Advanced Oncotherapy. Jeffrey K. Aronson has written articles and edited textbooks and has given medicolegal advice about adverse drug reactions. Giovanni Furlan is an employee of Pfizer s.r.l. and owns stocks in Pfizer, as well as other pharmaceutical companies through exchange traded funds. Kenneth Hartigan-Go declares that since 2018 he has been a respondent in legal cases in the Philippines involving the vaccine product Dengvaxia. D.K. Theo Raynor is co-founder and academic advisor to Luto Research, which was a spinout company of the University of Leeds, and develops, refines and tests health information; he is also co-chair of the Patient Safety Communication Advisory Panel at Bayer AG, Berlin. Gianluca Trifir\u00f2 attended seminars and advisory boards funded by pharmaceutical companies on topics not related to the contents of this article, as head of a pharmacoepidemiological team at the University of Messina (until October 2020), and now of the academic spinoff INSPIRE, coordinated some observational studies and a Master\u2019s programme, which received unconditional grants from several pharmaceutical companies; in addition, he participated in advisory boards that have been sponsored by several pharmaceutical companies; all these activities are not related to the topic of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable (as this is not a study report).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable (as this is not a study report).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The article is based on presentations at the ISoP events and other referenced materials, as well as personal notes taken by Priya\u00a0Bahri and Ulrich\u00a0Hagemann during the referenced sessions and meetings.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"The data and materials for this article were compiled by PB as the ISoP CommSIG Coordinator, and the article was drafted by PB and GB. Contributions to the content were made as follows: CA, JKA, PB, AC-R, BDE, IF, MIG, FH, BPJH, PGM, HN, YO and DKR as leads and presenters of referenced abstracts\/oral presentations for sessions on risk communication during ISoP annual meetings underpinned by slides and\/or scripts; MB, FS and JS as leads of referenced abstracts for sessions on risk communication during ISoP annual meetings; RD, GN and GT as abstract co-authors and presenters for sessions on risk communication during ISoP annual meetings, as referenced; PB, BDE and KI as session chairs for sessions on risk communication during ISoP annual meetings, as referenced; GB and PB through reviewing and selecting the poster abstracts for Appendix 2; WG as an additional expert who provided draft text for the article; and CA, JKA, AC-R, BDE, GF, KYH, BPJH, KI, PGM and GT through comments on the draft article. All authors reviewed and approved the final version of this article.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}